Seth Lederman Purchases 5,000 Shares of Tonix Pharmaceuticals (NASDAQ:TNXP) Stock

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Seth Lederman purchased 5,000 shares of the business’s stock in a transaction on Tuesday, June 9th. The stock was purchased at an average price of $11.79 per share, with a total value of $58,950.00. Following the purchase, the chief executive officer owned 9,005 shares of the company’s stock, valued at approximately $106,168.95. The trade was a 124.84% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Seth Lederman also recently made the following trade(s):

• On Wednesday, March 18th, Seth Lederman purchased 15,000 shares of Tonix Pharmaceuticals stock. The stock was purchased at an average price of $14.89 per share, with a total value of $223,350.00.

Tonix Pharmaceuticals Price Performance

Shares of TNXP stock opened at $10.96 on Thursday. The stock has a market cap of $174.70 million, a P/E ratio of -0.76 and a beta of 1.67. The company has a fifty day moving average price of $13.15 and a two-hundred day moving average price of $14.99. Tonix Pharmaceuticals Holding Corp. has a one year low of $10.87 and a one year high of $69.97.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings results on Monday, May 11th. The company reported ($2.93) EPS for the quarter, missing analysts’ consensus estimates of ($2.54) by ($0.39). Tonix Pharmaceuticals had a negative net margin of 839.52% and a negative return on equity of 67.65%. The firm had revenue of $6.88 million during the quarter, compared to analyst estimates of $6.13 million. As a group, equities research analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -9.94 EPS for the current fiscal year.

Institutional Trading of Tonix Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Legal & General Group Plc acquired a new stake in Tonix Pharmaceuticals in the 2nd quarter worth about $25,000. Strs Ohio raised its stake in Tonix Pharmaceuticals by 9.9% in the 4th quarter. Strs Ohio now owns 7,800 shares of the company’s stock worth $122,000 after purchasing an additional 700 shares in the last quarter. Rhumbline Advisers raised its stake in Tonix Pharmaceuticals by 8.0% in the 3rd quarter. Rhumbline Advisers now owns 12,206 shares of the company’s stock worth $295,000 after purchasing an additional 908 shares in the last quarter. Bank of America Corp DE raised its stake in Tonix Pharmaceuticals by 32.7% in the 3rd quarter. Bank of America Corp DE now owns 4,651 shares of the company’s stock worth $112,000 after purchasing an additional 1,146 shares in the last quarter. Finally, Russell Investments Group Ltd. acquired a new stake in Tonix Pharmaceuticals in the 3rd quarter worth about $29,000. Institutional investors and hedge funds own 82.26% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on TNXP shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a research note on Monday, April 20th. Wall Street Zen cut shares of Tonix Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, April 26th. Finally, TD Cowen upgraded shares of Tonix Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, May 5th. One research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $22.00.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.